Hopefully, continued publications related to the efficacy of mifepristone for treating various cancers will generate interest in some oncologists to initiate larger clinical trials or generate interest in some pharmaceutical companies to try to develop and patent even more efficacious P receptor modulators, or possibly explore the use of monoclonal antibody therapy directed against PIBF. This evidence concerns the gene PIBF1 and cancer.